ESLA compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

ESLAEstrella Immunopharma, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

ESLAEstrella Immunopharma, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Revenue flow

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

ESLAEstrella Immunopharma, Inc.

0.41▼−6.83%

Mkt cap$19.3MRevenue—Revenue—

AMGNAmgen Inc

468.02▼−2.19%

Regular sessionNov 5 '26

Mkt cap$258.8BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

Regular sessionNov 5 '26

ESLAEstrella Immunopharma, Inc.

AMGNAmgen Inc

0.41▼−6.83%

Price

468.02▼−2.19%

$19.3M

Mkt cap

$258.8B

—

Revenue

$10.4BQ3 FY26

—

Revenue

$36.8BFY25

ESLA0.41▼−6.83%vsAMGN468.02▼−2.19%Regular sessionNov 5 '26

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Price

Supply-chain overlap

Revenue flow

ESLA: latest quarter not drawable.Method ›

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ESLA 1

—Eureka Therapeuticsunlistedsupplier

Shared 0

No shared counterparties.

Only AMGN 12

PODDInsuletsupplier

CYTKCytokineticssupplier

ARWRArrowhead Pharmaceuticalssupplier

LGNDLigand Pharmaceuticalssupplier

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

8 more · AMGN chain ›

Price

rebased to 0%

ESLA, solidAMGN, dashed